Molecular Metabolism (Sep 2024)

Cathepsin D is essential for the degradomic shift of macrophages required to resolve liver fibrosis

  • Paloma Ruiz-Blázquez,
  • María Fernández-Fernández,
  • Valeria Pistorio,
  • Celia Martinez-Sanchez,
  • Michele Costanzo,
  • Paula Iruzubieta,
  • Ekaterina Zhuravleva,
  • Júlia Cacho-Pujol,
  • Silvia Ariño,
  • Alejandro Del Castillo-Cruz,
  • Susana Núñez,
  • Jesper B. Andersen,
  • Margherita Ruoppolo,
  • Javier Crespo,
  • Carmen García-Ruiz,
  • Luigi Michele Pavone,
  • Thomas Reinheckel,
  • Pau Sancho-Bru,
  • Mar Coll,
  • José C. Fernández-Checa,
  • Anna Moles

Journal volume & issue
Vol. 87
p. 101989

Abstract

Read online

Background and objectives: Fibrosis contributes to 45% of deaths in industrialized nations and is characterized by an abnormal accumulation of extracellular matrix (ECM). There are no specific anti-fibrotic treatments for liver fibrosis, and previous unsuccessful attempts at drug development have focused on preventing ECM deposition. Because liver fibrosis is largely acknowledged to be reversible, regulating fibrosis resolution could offer novel therapeutical options. However, little is known about the mechanisms controlling ECM remodeling during resolution. Changes in proteolytic activity are essential for ECM homeostasis and macrophages are an important source of proteases. Herein, in this study we evaluate the role of macrophage-derived cathepsin D (CtsD) during liver fibrosis. Methods: CtsD expression and associated pathways were characterized in single-cell RNA sequencing and transcriptomic datasets in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD and hepatocyte-CtsD knock-out mice. Results: Analysis of single-cell RNA sequencing datasets demonstrated CtsD was expressed in macrophages and hepatocytes in human cirrhosis. Liver fibrosis progression, reversion and functional characterization were assessed in novel myeloid-CtsD (CtsDΔMyel) and hepatocyte-CtsD knock-out mice. CtsD deletion in macrophages, but not in hepatocytes, resulted in enhanced liver fibrosis. Both inflammatory and matrisome proteomic signatures were enriched in fibrotic CtsDΔMyel livers. Besides, CtsDΔMyel liver macrophages displayed functional, phenotypical and secretomic changes, which resulted in a degradomic phenotypical shift, responsible for the defective proteolytic processing of collagen I in vitro and impaired collagen remodeling during fibrosis resolution in vivo. Finally, CtsD-expressing mononuclear phagocytes of cirrhotic human livers were enriched in lysosomal and ECM degradative signaling pathways. Conclusions: Our work describes for the first-time CtsD-driven lysosomal activity as a central hub for restorative macrophage function during fibrosis resolution and opens new avenues to explore their degradome landscape to inform drug development.

Keywords